Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 15/20 | 0.37 |
| ▸ | CDK9 | P50750 | 15/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980834 | 0.94 | CCNT1 (0.37) | CCNT1CDK9PTGDRENPP2TDO2 | |
| SCHEMBL980915 | 0.88 | CCNT1 (0.48) | CCNT1CDK9 | |
| SCHEMBL978848 | 0.83 | CCNT1 (0.42) | CCNT1CDK9PTGDRTDO2LMNA | |
| SCHEMBL982441 | 0.81 | CCNT1 (0.37) | CCNT1CDK9PTGDRENPP2TDO2 | |
| SCHEMBL9947643 | 0.80 | CCNT1 (0.36) | CCNT1CDK9PTGDRENPP2TDO2 | |
| SCHEMBL9947615 | 0.80 | CCNT1 (0.36) | CCNT1CDK9PTGDRENPP2TDO2 | |
| SCHEMBL979615 | 0.79 | CCNT1 (0.38) | CCNT1CDK9PTGDRTDO2LMNA | |
| SCHEMBL981820 | 0.77 | PTGDR (0.39) | CCNT1CDK9PTGDRENPP2TDO2 | |
| SCHEMBL1052390 | 0.75 | ADORA3 (0.44) | CCNT1CDK9TDO2 | |
| SCHEMBL980281 | 0.75 | TDP1 (0.48) | CCNT1CDK9TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207344-B2 | GPR119 agonists | ELI LILLY AND COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2454251-A1 | GPR119 AGONISTS | Eli Lilly and Company (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008663-A1 | GPR119 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015199-A1 | GPR119 Agonists | ELI LILLY AND COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015199-A1 | GPR119 Agonists | GPR119, GLP1R, GCGR | CCNT1 4475/4885CDK9 2128/4885PTGDR 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.